All News

After 14 months without ART, a patient with HIV only had transient detection of trace levels of HIV DNA in her blood cells after a stem cell transplant for acute myeloid leukemia.

Sara Wettergreen, assistant professor in the department of Clinical Pharmacy and Department of Family Medicine at Skaggs School of Pharmacy and Pharmaceutical Sciences, discusses burnout and mental health concerns among pharmacy technicians.

The combination of albuterol/budesonide shows promise in lowering the risk of severe exacerbations and improved lung function compared to albuterol as a rescue inhaler in patients with asthma.

Lifestyle-related factors, including food consumption, may significantly increase the chance of triggering a migraine headache.

Adenovirus has been noted in some patients throughout Europe, but not among all of them so investigators are considering other potential causes and contributing factors in the hepatitis outbreak.

Evidence suggests that there are many barriers to the proper implementation of MTM services, including time constraints and lack of staff support.

Students are being exposed to new patient experiences through collaboration with practitioners.

Baricitinib (Olumiant) approved for the treatment of adult patients hospitalized with COVID-19 who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Vosevi is a fixed-dose combination for the treatment of hepatitis C virus.

The PQA team is diverse, and they have expertise in quantitative research as well as quality.

These measures are specified for application to pharmacies, as opposed to health plan measures.

Joel Wayment, vice president of operations for 3PL Services at Cardinal Health, discusses how the pharmaceutical supply chain currently manages the transport of CAR T products to sites of administration.

Medications are the primary cause of acquired QT-prolongation, although the exact mechanism of why some people evoke torsades de pointes but others do not is still unknown.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses blockbuster drugs in the oncology space that have been approved this year or may be hitting the market soon.

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses state and federal legislation that may be impacting the future of specialty pharmacies and the patient care they deliver.

Metformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.

Cara McNulty, president of Behavioral Health and Mental Well-Being at CVS Health, discusses a recently published survey from CVS Health Study on rising concerns of mental health in Americans.

Metronidazole is commonly used to treat Clostridium difficile infection, however, it has higher rates of therapy failure.

Investigators develop a genetic-risk score to identify those who would benefit most from lifestyle counseling to prevent the condition.

Second analysis indicates that parents of children with food allergies became less anxious during the pandemic.

Students in the ISU/UAA pharmacy program discuss the impact of Alaska’s first pharmacy program and what it means to learn about and work in rural communities.

Vedolizumab (Entyvio) is indicated for adult patients with moderately to severely active ulcerative colitis and adult patients with moderately to severely active Crohn disease.

Oxy-Powder is designed to clean the digestive tract and oxidize and decrease the amount of impacted fecal matter.

National Asthma and Allergy Awareness Month highlights how pharmacists in all health care settings are in a unique position to improve management and outcomes of individuals with these conditions.

Imposter syndrome is a phenomenon that affects self-confidence, significantly limiting the effectiveness of professionals affected by it.

Analysis shows that half of individuals with both these sensory losses are cognitively impaired, investigators say.

Results from the DELIVER and DAPA-HF phase 3 trials demonstrate AstraZeneca’s Farxiga’s efficacy in heart failure, regardless of ejection fraction.

An international phase 1/2 clinical trial is ongoing for the treatment for individuals with relapsed or refectory acute myeloid leukemia with FLT3 mutation.